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Abstract
Many hereditary cancer syndromes are associated with an increased risk of small and large intestinal adenocarcinomas.
However, conditions bearing a high risk to both adenocarcinomas and neuroendocrine tumors are yet to be described. We
studied a family with 16 individuals in four generations affected by a wide spectrum of intestinal tumors, including
hyperplastic polyps, adenomas, small intestinal neuroendocrine tumors, and colorectal and small intestinal
adenocarcinomas. To assess the genetic susceptibility and understand the novel phenotype, we utilized multiple molecular
methods, including whole genome sequencing, RNA sequencing, single cell sequencing, RNA in situ hybridization and
organoid culture. We detected a heterozygous deletion at the cystic fibrosis locus (7q31.2) perfectly segregating with the
intestinal tumor predisposition in the family. The deletion removes a topologically associating domain border between CFTR
and WNT2, aberrantly activating WNT2 in the intestinal epithelium. These consequences suggest that the deletion
predisposes to small intestinal neuroendocrine tumors and small and large intestinal adenocarcinomas, and reveals the
broad tumorigenic effects of aberrant WNT activation in the human intestine.
Introduction
Intestinal cancer syndromes, such as Lynch syndrome, familial
adenomatous polyposis, juvenile polyposis syndrome and Peutz-
Jeghers syndrome are associated with elevated relative risk
of small and large intestinal adenocarcinomas. An increasing
amount of research has also described the familial occurrence
of small intestinal neuroendocrine tumors (SI-NETs) (1–4).
Occasionally, SI-NETs may also develop in individuals with
menin 1 (MEN1), ret proto-oncogene (RET) and neurofibromin
1 (NF1) germline mutations, and in more recent studies,
inositol polyphosphate multikinase (IPMK) and mutY DNA
glycosylase (MUTYH) have been suggested as predisposition
genes (5,6). However, Mendelian conditions bearing a high risk
to both intestinal adenocarcinomas and SI-NETs have not been
described.
Studies on the three-dimensional genome organization have
demonstrated that mammalian chromosomes partition into
self-interacting domains, known as topologically associating
domains (TADs) (7,8). Genomic regions in these interact with
each other more frequently than with the surrounding regions,
and genes within TADs have been shown to be often co-regulated
(7,8). Disruption of a TAD border may result in aberrant genomic
interactions, disturbed gene regulation and disease (9).
Here, we describe a family with multiple individuals segre-
gating small and large intestinal epithelial cancers, including
neuroendocrine tumors and adenocarcinomas. Several family
members also had intestinal hyperplasias and adenomas. Using
whole genome sequencing and linkage analysis, we identified
a 121.1 kb heterozygous deletion at the cystic fibrosis locus
(7q31.2), segregating with the intestinal neoplasms in the family.
The deletion removes a TAD border between CF transmembrane
conductance regulator (CFTR) and Wnt family member 2 (WNT2),
inactivating the former and activating the latter in the intestinal
epithelium of the deletion carriers. To our knowledge, this is
the first report of TAD border disruption as a likely cause for
cancer predisposition, emphasizing the value of whole genome
sequencing in detecting disease-causing variants.
Results
The family included 16 individuals with confirmed intestinal
tumors in four generations (Fig. 1). The proband (IV-8) had a
history of prolonged diarrhea, flushing and wheezing, and was
diagnosed with multiple ileal neuroendocrine tumors with liver
metastases and carcinoid syndrome at the age of 48. Fourteen
years later, he was also diagnosed with locally metastasized
duodenal adenocarcinoma. He regularly undergoes colonoscopy
and numerous hyperplastic polyps and adenomas have been
removed. His son (V-2), sister (IV-9), mother (III-7), aunt (III-
6), cousin (IV-2) and second cousin (IV-4) have also been
diagnosed with multiple (in some cases up to hundreds) SI-
NETs (Fig. 1, Supplementary Material, Table S1). Five of these
patients had local or distant metastases, and all examined SI-
NETs were well differentiated, gradus 1 (Ki 67; < 2%) tumors
and stained positive for synaptophysin and chromogranin A
(Supplementary Material, Tables S1 and S2).
Other intestinal cancers in the family include small
intestinal adenocarcinoma (ampulla of vater: III-1 and III-5)
and colorectal carcinoma (unspecified rectal carcinoma: II-2,
and adenocarcinomas: II-4, III-1 and III-4). Several individuals
had been diagnosed with benign intestinal lesions, including
ampulla of vater adenoma (III-3 and IV-6), ileal hyperplasia or
adenoma (IV-2 and IV-1), as well as hyperplastic polyps and
adenomas of the large intestine (III-1, III-4, III-6, IV-1, IV-2, IV-
3, IV-6, IV-9, V-1 and V-2). These were often multiple, and in
the clinical records of IV-9, they were referred to as polyposis
(Supplementary Material, Table S1). One gastrointestinal cancer
with unspecified location (II-1) and one gastric adenocarcinoma
(III-2) was also present in the family (Fig. 1). The family members
are regularly followed-up at the clinic, and certain tumor diag-
noses of IV-1, IV-3, IV-6, IV-8, V-1 and V-2 have been made during
the follow-up. Details of the tumor diagnoses and other clinical
data are summarized in Supplementary Material, Table S1.
To understand the molecular basis of the intestinal tumor
predisposition in the family, we first focused on the patients
with multiple SI-NETs, as this rare phenotype carried a
low possibility of phenocopies. That is, individuals with
this disease were likely to carry a predisposing change,
rather than being incidental. To map the genomic regions
shared by the SI-NET patients, we performed linkage anal-
ysis, which resulted in 239.3 centimorgan (cM) of candidate
genomic regions with positive logarithm of the odds (LOD)
score (Supplementary Material, Table S3). To assess the single
nucleotide variants and small insertions and deletions within
these regions, we whole genome sequenced the germline DNAs
of four SI-NET patients (Supplementary Material, Table S4), and
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Figure 1. Pedigree of the family with multiple intestinal tumors. The proband (IV-8) is indicated with an arrow. Heterozygous deletion carriers are marked with MUT
and wild-type allele carriers with WT sign. Squares denote males and circles females. Diamond symbol marks individuals whose gender is unknown and diagonal line
marks the deceased. Generations are marked with roman numbers and individuals with Arabic numbers. The pedigree has been modified for confidentiality.
minor allele frequency (MAF) > 0.001 in the Genome Aggregation
Database (gnomAD, http://gnomad.broadinstitute.org/), and in
the Finnish individuals in gnomAD, a single shared protein
coding variant remained (Supplementary Material, Table S5).
This missense variant (p.Arg362Trp, rs756287596) in Tumor
Suppressor Protein 73 (TP73) was in silico predicted damaging
(Polyphen2: probably_damaging, score 1.000; PROVEAN: deleteri-
ous, score − 6.57). However, when we screened the variant in the
remaining three SI-NET patients (III-7, IV-1, and IV-2), it was not
detected in IV-1, although multiple independent samples were
studied. We also screened the variant in healthy geographically
matched control individuals and it was present in two out of the
365 individuals (MAF = 0.003).
We next studied the whole genomes for shared rare struc-
tural variants (SVs) and identified a heterozygous 121.1 kb dele-
tion in 7q31.2 (Fig. 2). The deletion segregated in all seven SI-NET
patients and the exact position of the deletion (Chr7:117003533-
117 124 613; GRCh37) was determined by Sanger sequencing
(Supplementary Material, Fig. S1). The germline whole genomes
of 327 Finnish control individuals were all negative for the
deletion, as were 313 additional healthy geographically matched
controls screened for the deletion. The deletion was further
screened in in the extended pedigree and was shown to
segregate perfectly also with the other intestinal neoplasms
in the family (Fig. 1). We additionally screened the deletion in
49 unrelated Finnish SI-NET patients, of which four had a first
degree relative with SI-NET, and 29 had multiple tumors at the
time of diagnosis, but identified none of them to harbor the
deletion.
The deletion spans from the 3’UTR of Ankyrin repeat, SAM
and basic leucine zipper domain containing 1 (ASZ1) to the
first intron of CFTR removing exon 1 (Fig. 2). Moreover, the
deletion overlaps a previously characterized TAD boundary
(10) located within ASZ1, separating CFTR and WNT2 in two
separate TADs (Fig. 2B). To study the effect of the deletion on
the regulation of nearby genes, we extracted and sequenced the
RNAs of four small intestinal samples (three neuroendocrine
tumors and a normal ileum sample) from a deletion carrier
(V-2), and compared the data to small intestinal control
tissue data (n = 4, Supplementary Material, Table S4) (11). We
scrutinized the entire chromosome 7 candidate genomic region
(Chr7:105323488-123 764 045; GRCh37), including ASZ1, CFTR and
WNT2 and encompassing altogether 72 protein coding genes.
The most differentially expressed gene was WNT2 (log2 fold
change: 4.9, false discovery rate [FDR] adj. P-value 1.4E-11).
CFTR expression was slightly reduced (log2 fold change: −1.1,
FDR adj. P-value: 0.060) and ASZ1 expression was not detected
(Supplementary Material, Table S6). When we compared tumors
to normals (V-2 SI-NETs compared to V-2 normal sample
and control data), WNT2 expression was not significantly
altered (log2 fold change: 0.63, adj. P-value: 0.40), whereas CFTR
expression was slightly decreased (log2 fold change: −0.84, FDR
adj. P-value: 0.0028; Supplementary Material, Table S7).
To further study the WNT2 up-regulation, we extracted
RNA from colonoscopy biopsies from three deletion carriers
(IV-1, IV-6 and V-2) and RNA sequenced the samples. When
we compared the colonoscopy biopsies (tumors and normal
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Figure 2. Deletion in 7q31.2 removes a topology associating domain border. (A) Drop in the sequencing reads (black) in the whole genome sequence data at the site of
the heterozygous deletion. Whole genome sequence reads are visualized with BasePlayer (16). (B) The deletion spans a TAD border between CFTR and WNT2. The Hi-C
interaction heatmap (red triangles) was obtained from 3D Genome browser (http://3dgenome.fsm.northwestern.edu/view.php), and is based on the data generated
from GM12878 (Lieberman-raw; 25 kb resolution, hg19) (10).
Supplementary Material, Table S4), WNT2 showed again striking
up-regulation and was the sixth most variable gene among all
protein coding genes (log2 fold change: 9.0, FDR adj. P-value:
3.29E-115; Supplementary Material, Table S8).
To confirm that the observed WNT2 up-regulation resulted
due to the deletion, we studied the allele-specific expression
of WNT2. Two deletion carriers (IV-1 and V-2) had heterozygous
germline SNPs (rs2024233, rs3840660 and rs4730775) in the 3’UTR
of WNT2. We inspected the allele balance of these SNPs in the
RNA sequenced intestinal samples of IV-1 and V-2, and observed
monoallelic WNT2 expression. This was further confirmed by
cDNA sequencing (Supplementary Material, Fig. S2a). The same
applied to CFTR at the site of two informative germline SNPs
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Further haplotype analysis confirmed that the monoallelic
WNT2 expression originated from the deletion harboring
allele, whereas the monoallelic CFTR expression from the
unaffected allele. Of note, we also studied intestinal biopsies
of a non-deletion carrier (IV-5), who also harbored het-
erozygous germline SNPs in WNT2 and CFTR. As expected,
we observed biallelic expression of CFTR in his samples
(Supplementary Material, Fig. S2b). Despite various efforts, we
failed to amplify WNT2 in his samples, likely due to low basal
expression of WNT2 in the normal gastrointestinal tract (https://
gtexportal.org/, v7).
To study the morphological location of WNT2 and CFTR
expression in the tumors of the deletion carriers, we performed
RNA in situ hybridization. Tissue samples from sporadic cases
were stained as comparison. The sporadic subjects were
confirmed not to have close relatives diagnosed with the
same tumor type and not to carry the 7q31.2 deletion. CFTR
expression was abundant in the intestinal epithelium of the
deletion carriers and sporadic cases (Fig. 3A-B). However, WNT2
expression was detected only in the intestinal epithelium of
the deletion carriers (Fig. 3A-B). SI-NETs were devoid of CFTR
and WNT2 expression (Fig. 3C-D), whereas both genes were
expressed in the adenocarcinomas (Fig. 3A) and colorectal
adenomas (Supplementary Material, Fig. S3) of the deletion
carriers.
To further examine if WNT2 and CFTR were expressed by
the same cells, we performed single cell RNA-sequencing and
gene expression analysis of normal ileum and ileal adenoma of a
deletion carrier (IV-1, Supplementary Material, Fig. S4). Although
initially suspected as SI-NET in the computer tomography, the
tumor was later in the pathological review confirmed to be
an ileal adenoma with no evidence of neuroendocrine tumor.
Compatible with our hypothesis that the WNT2 up-regulation
stems from the TAD breakage, causing CFTR regulatory ele-
ments to drive WNT2 expression, cells expressing both WNT2
and CFTR were enriched (normal sample, P-value: 0.0085, 95%
confidence interval [CI] 0.0011–0.0042, adenoma sample, P-value:
8.65E-12, 95% CI 0.016–0.024, two-sided exact binomial test).
However, in the normal ileum, WNT2 expression was mostly
present in the predicted crypt cells, whereas CFTR expression
was seen in many different epithelial cell types (Fig. 4). In the
adenoma, both genes were expressed across different cell types
(Fig. 4). We also studied if WNT2 expression was associated
with expression of enteroendocrine cell/neuroendocrine tumor
markers chromogranin A (CHGA) and synaptophysin (SYP). CHGA
expression was detected only in 1/97 and 2/448 WNT2 express-
ing cells in the normal ileum and ileal adenoma, respectively.
SYP expression was more prevalent in the samples, and was
shown to be associated with WNT2 expression, especially in the
adenoma cells (normal sample P-value: 0.0025, 95% CI 0.0014–
0.0048; adenoma sample P-value: 8.864E-07, 95% CI 0.017–0.025,
two-sided exact binomial test, Fig. 4). It was of particular interest
to see that the expression of OLFM4 (olfactomedin 4) and EPHB2
(EPH Receptor B2), both established intestinal stem cell markers,
were strongly associated with WNT2 expressing cells (normal
sample: OLFM4 P-value: 2.20E-16, 95% CI 0.010–0.017; EPHB2 P-
value: 6.588E-12, 95% CI 0.0028–0.0070; adenoma sample: OLFM4
P-value: 6.99E-12, 95% CI 0.074–0.090; EPHB2 P-value: 2.2E-16,
95% CI 0.027–0.037, two-sided exact binomial test) (Fig. 4) sug-
gesting autocrine regulation of WNT activity in the stem cells
(Fig. 4).
Finally, to investigate if the aberrant WNT2 secretion could
drive the neoplastic growth, we cultured organoids from intesti-
nal biopsies of a deletion carrier (V-1), and two age and sex
matched controls (Supplementary Material, Table S4). Intestinal
organoids require activation of the canonical WNT pathway
for normal growth, which can be obtained by adding GSK3β
inhibitor (CHIR99021, GSK3βi) into the culture media. To test if
the deletion carriers’ organoids could survive without exogenous
WNT pathway activation, organoids were grown in lowering con-
centrations of GSK3βi. As demonstrated in Figure 5, the deletion
carriers’ organoids remained vital even in the absence of GSK3βi.
The effect was present regardless of the intestinal location of the
organoids, but most evident in the colonic organoids (Fig. 5B-C).
Strikingly, WNT activation in deletion carriers’ cells was able to
sustain clonal growth of single cells (Fig. 5D). To confirm that
the observed growth benefit was due to excess production of
WNT ligands, we utilized porcupine inhibitor (IWP-2, PORCNi),
which prevents acylation and secretion of WNT ligands (12).
PORCNi abolished the organoid growth in GSK3βi free media
(Fig. 5D). Together these data demonstrate that aberrant growth
in deletion carriers’ organoids was due to excessive production
of WNT ligand.
Taken together, our genetic and functional data support the
hypothesis that the deletion at 7q31.2 leads to aberrant activa-
tion of WNT2 resulting in niche independent growth of intestinal
stem cells.
Discussion
High relative risk to intestinal adenocarcinoma is a characteristic
feature of several well established intestinal cancer syndromes.
SI-NETs have also been reported to cluster in families (1–4),
and occasionally manifest in individuals with Mendelian disor-
ders, such as Multiple endocrine neoplasms (MEN1) and neu-
rofibromatosis 1 (NF1). To the best of our knowledge, Mendelian
conditions causing a high risk to intestinal adenocarcinomas
as well as neuroendocrine tumors have not been previously
described.
By studying a family with 16 affected individuals, we identi-
fied a heterozygous deletion at the cystic fibrosis locus (7q31.2)
perfectly segregating with the intestinal cancers in the fam-
ily. The deletion was further screened in 49 additional SI-NET
patients, but no additional deletion carriers were found, and
it is likely that the particular deletion is private to the family.
Thorough screening of the locus, with methods that can detect
other TAD breaking chromosomal alterations and WNT2 activat-
ing mutations is warranted in patients with similar phenotype
to the family.
The deletion disrupts the TAD border between two genes
(CFTR and WNT2) and leads to aberrant expression of WNT2
from the deletion allele in the intestinal epithelium. The genetic
findings, supported by the functional experiments, suggest a
new cancer syndrome caused by aberrant activation of WNT2
that predisposes to SI-NETs and intestinal adenocarcinomas.
WNT2 encodes a secreted signaling protein normally
expressed in the placenta and in adult tissues primarily in
the lung. It can activate the canonical WNT signaling pathway,
crucial for the intestinal stem cell regulation. Aberrant activation
of the canonical WNT pathway is considered an essential early
event in the colorectal carcinogenesis, and overexpression of
WNT2 has been reported in esophageal, colorectal and gastric
cancers (13–15).
CFTR encodes a chloride channel that regulates ion and water
secretion and absorption. Its expression is highly tissue specific,
and is most abundant in the intestinal epithelium. In the esoph-
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Figure 3. WNT2 is expressed in the normal intestinal epithelium and adenocarcinomas of the deletion carriers. (A-F) RNA in situ hybridization of CFTR (green) and
WNT2 (red) in normal intestinal epithelium and tumors of a deletion carrier and a sporadic patient. The nuclei are stained with DAPI (blue). Identical image settings
were used for the compared tissue types. Following signal intensity settings were used: DAPI 90, Cy3 150 and Cy5 30 (A, B), DAPI 90, Cy3 150, Cy5 30 (C, D), DAPI 80, Cy3
90 and Cy 50 (E, F). A, Normal small intestinal epithelium of a deletion carrier and b, a sporadic patient shows uniform expression of CFTR. A, WNT2 is expressed only
in the intestinal epithelium of the deletion carrier. C, Small intestinal neuroendocrine tumor of a deletion carrier and D, a sporadic patient displays no expression of
CFTR or WNT2. E, Colorectal adenocarcinoma of a deletion carrier and F, a sporadic patient show uniform expression of CFTR. E, WNT2 expression is present only in the
adenocarcinoma of the deletion carrier.
rg/, v7). CFTR expression is regulated by well-documented tissue-
specific enhancers located in introns 1, 10 and 11 that inter-
act with the CFTR promoter via chromosomal looping (16,17).
We hypothesized that by removing the TAD border between
CFTR and WNT2 and the CFTR promoter, the deletion rewires
the intestine specific enhancers of CFTR to interact with the
WNT2 promoter, aberrantly activating its secretion in the non-
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Figure 4. WNT2 expression is enriched among the intestinal crypt cells and enteroendocrine cell marker SYP. (A) Upper panel left: K-means 10 clustering of the single
cell gene expression data of the normal ileum sample of patient IV-1. Cluster IDs: 1–2 (epithelial cells), 3 (cells with low gene expression of mainly mitochondrial genes),
4 (immune cells, mainly T and B lymphocytes), 5 (crypt cells), 6 (complement components expressing cells), 7–8 (miscellaneous), 9 (adipose cells), 10 (muscle cells).
Upper panel middle, right and lower panel: Single cells from the normal ileum expressing WNT2, CFTR, SYP, OLFM4 and EPHB2. Color scale represents the normalized
and log2-transformed expression of the gene. (B) Upper panel left: K-means 10 clustering of the single cell gene expression data of the ileal adenoma of patient IV-1.
Cluster IDs: 1–2 (epithelial cells), 3 (immune cells, mainly B lymphocytes), 4 (crypt cells), 5 (enteroendocrine/secretory cells), 6 (immune cells, likely T lymphocytes),
7–10 (miscellaneous cells). Upper panel middle and right and lower panel: Single cells from the ileal adenoma expressing WNT2, CFTR, OLFM4 and EPHB2. Color scale
represents the normalized and log2-transformed expression of the gene.
would be expected to overlap with those expressing also the
normal CFTR allele, which indeed was the case.
However, it is also expected that the set of transcription
factors required for WNT2 expression and secretion would be
somewhat different from those required for CFTR expres-
sion. Such factors might in particular be available in the
intestinal crypt cells, as suggested by the co-expression of







g/article/30/24/2429/6323170 by guest on 29 D
ecem
ber 2021
2436 Human Molecular Genetics, 2021, Vol. 30, No. 24
Figure 5. 7q31.2 deletion carriers’ intestinal organoids are maintained without in vitro activation of the canonical WNT pathway. (A) Representative images of the colonic
organoids grown four days in reducing concentration of GSK3β inhibitor (GSK3βi) in the culture media. Scale bar 200 μm. (B) Duodenal and ileal organoids from 7q31.2
deletion carrier (V-1), and ileal and colonic organoids from two controls cultured in the absence of GSK3βi. Scale bar 200 μm (C) Frequency of the surviving organoids
after four days in reducing concentration of GSK3βi, (D) Relative number and representative images of single cells derived organoids grown in reducing GSK3βi and
increasing porcupine inhibitor (PORCNi) concentrations. Images and quantification are done six days post plating. Quantitative data collected from three replicates of
two different passages derived from the same organoid culture (V-1). For controls the data was collected from three replicates of two different colon organoid cultures.
Scale bar 100 μm.
Interestingly, WNT2 expression was also associated with
enteroendocrine/neuroendocrine tumor marker SYP expressing
cells especially in the intestinal adenoma of IV-1, which
was pathologically confirmed to be tubulovillous adenoma
with high-grade dysplasia and not to have evidence of neu-
roendocrine tumor. The resulting aberrant intestinal crypt
compartment would have potential to profoundly enhance







g/article/30/24/2429/6323170 by guest on 29 D
ecem
ber 2021
Human Molecular Genetics, 2021, Vol. 30, No. 24 2437
the studied family. In the intestinal tumors, WNT2 expression
was abundant in the adenomas and carcinomas of the deletion
carriers, but not detected in SI-NET tissue. This could be due to
silencing of the CFTR enhancer function during neuroendocrine
tumor development, a hypothesis requiring further validation.
The deletion, removing the first exon of CFTR, inactivates the
affected gene copy. This renders the deletion carriers also as
unaffected cystic fibrosis carriers. One manifestation of cystic
fibrosis is increased risk of gastrointestinal cancers (18,19). The
standard incidence ratio (SIR) has been reported to be particu-
larly high for gallbladder/extra hepatic bile duct cancers (SIR:
31.9, 95% CI: 1.6–159.0) and small intestinal cancers (SIR: 52.5,
95% CI: 8.8–175.0) in transplanted cystic fibrosis patients (18).
Although the risks are high, manifestation of these tumors are
rare, and in the largest study reported to date, with 41 188 cystic
fibrosis patients, only five small intestinal and four gallblad-
der/extra hepatic bile duct tumors were reported (19). Detailed
histology was described only for one of the small intestinal can-
cers, and it was reported to be carcinoid tumor (neuroendocrine
tumor) of the terminal ileum (18). Interestingly, heterozygous
CFTR (F508del) mutation carrier status has been recently asso-
ciated with increased risk for colorectal and gallbladder/bil-
iary tract cancer, but not with small intestinal cancer (20). Fur-
thermore, evidence exists that CFTR is a potential tumor sup-
pressor gene for mouse intestinal and human colorectal can-
cers (21). Taken together, it is not possible to unambiguously
exclude that in addition to WNT2, CFTR or other genetic mod-
ifiers, would contribute to the observed phenotype. Whether
the vicinity of WNT2 locus contributes to intestinal cancer pre-
disposition in cystic fibrosis mutation carriers remains to be
examined.
While most genes involved in Mendelian disease predispo-
sition may have been identified, structural variation in TAD
borders has the potential to lead to previously uncharacter-
ized familial high-penetrance disease phenotypes. The exis-
tence of this type of pathogenic variation speaks for utiliza-
tion of whole genome sequencing in diagnostic efforts tack-
ling apparently Mendelian conditions that are resistant to more
limited approaches. The results also emphasize the potential
of the emerging WNT inhibitors in management of intestinal
neoplasia (22).
Materials and Methods
The study was approved by the Finnish Institute for Health
and Welfare (THL; 151/5.05.00/2017) and the Ethics Com-
mittee of the Hospital district of Helsinki and Uusimaa. All
participants who donated fresh tissue samples signed an
informed consent. The use of archival diagnostic specimens was
authorized by the National Supervisory Authority for Welfare
and Health (Valvira; 1423/06.01.03.01/2012). The samples and
their use in different experiments are summarized in the
Supplementary Material, Table S4.
Genetic analyses
Genotyping was performed using Illumina HumanOmni2.5 v1.0
SNP chips (Illumina), at the Institute for Molecular Medicine
Finland (FIMM [Helsinki, Finland]). Illumina Genomestudio v.2.0
(Illumina) was used for genotype calling. Genotypes with a Gen-
Call score < 0.15 were excluded. The CEPH population in the
HapMap phase II dataset was used to determine allele frequen-
cies (23) and genotypes with MAF ≥0.1 were selected for the
linkage analysis.
Parametric multipoint linkage analysis, with an autosomal
dominant inheritance model was performed with Merlin (v.1.1.2)
(24). In the analysis, all genotyped SI-NET patients (III-6, III-7, IV-
2, IV-8, IV-9, V-2) and the obligatory mutation carrier with col-
orectal adenocarcinoma (III-4) were marked as ‘affected’. Indi-
viduals I-1, I-2, II-1, II-4, II-5, III-1, IV-3, IV-4 and IV-6 were marked
as ‘missing phenotype’, and the spouses of II-1, III-4, III-6, III-7
and IV-8 as ‘unaffected’ (Supplementary Material, Fig. S5). Mer-
lin’s error detection algorithm and pedwipe command was uti-
lized to remove unlikely genotypes. Marker distances in cM were
determined based on the HapMap phase II genetic map (23), and
the parametric LOD scores calculated for equally spaced loca-
tions (option —grid 0.25) along the chromosomes. Chromosomal
regions with positive LOD score were determined and regions
within 1 cM distance were merged.
Whole genome sequencing libraries were prepared using
an Illumina TruSeq PCR-free library prep kit, and sequenced
(paired-end 150 bp reads) by Illumina HighSeq X Ten at
SciLife laboratory (Stockholm, Sweden). The reads were aligned
with Burrows-Wheeler Aligner (BWA)–MEM version 0.7.12
(25) against the GRCh37 genome from the 1000 Genomes
Project (human_g1k_v37.fasta). The variants were called with
HaplotypeCaller following GATK (v3.5) best practices (26,27).
The in-house whole genome sequencing pipeline is described
in more detail in (28). The mean coverage of the genomes
ranged from 30.7–32.3, and the number of mapped reads
exceeded 98.6%. Comparative variant analysis, polymorphism
filtering, annotation and variant visualization was performed
in BasePlayer (29), with Ensembl GRCh37 (release 84) genomic
annotation. Variants were required to have ≥10 read coverage
and ≥ 25% variant allele frequency, and excluded all the variants
residing outside the ‘Strict’ accessibility mask regions from 1000
Genomes phase 3 (30). We also exclude variants with MAF > 0.001
in the gnomAD, V2.0.1; http://gnomad.broadinstitute.org/) and
in the Finnish subset of gnomAD (n = 12 897).
Structural variants (SVs) were called using DELLY (v0.09)
(31,32) as described in (33). SVs that we considered further had
to be supported by at least three read pairs (34) and were not
allowed to be present in any of the 327 Finnish in-house control
whole genomes. We also excluded the SVs that resided outside
positive LOD score regions, or were not present in all four whole
genome sequenced affected individuals.
PCR and sanger sequencing and cDNA synthesis
PCRs were performed using AmpliTaq Gold DNA polymerase
(Applied Biosystems by Life Technologies). Products were run
on an agarose gel and purified using the A’SAP PCR cleanup
kit (Arctic Zymes) and Sanger sequenced at FIMM. Sequences
were analyzed manually and with Mutation Surveyor (v4.08)
(Softgenetics). PCRs from archival samples were performed in at
least three replicates. For cDNA synthesis, RNA was reverse tran-
scribed using random primers and Moloney Murine Leukemia
Virus (M-MLV) reverse transcriptase (Promega). The primers are
listed in Supplementary Material, Table S9 and were designed
with Primer3web (v4.0.0) (34,35).
RNA sequencing
Tissues were homogenized using Ultra Turrax® (IKA) and
RNA was extracted with the Qiagen RNeasy mini kit (Qiagen).
Sequencing libraries were prepared from total RNA (1 μg)
using the KAPA Stranded RNA-seq kit with RiboErase (Roche)







g/article/30/24/2429/6323170 by guest on 29 D
ecem
ber 2021
2438 Human Molecular Genetics, 2021, Vol. 30, No. 24
HiSeq4000 at Karolinska Institutet (Stockholm, Sweden), or with
HiSeq2500 at FIMM. All samples, regardless of their RNA integrity
numbers, were used for library preparation and sequencing
(Supplementary Material, Table S10). Data from four small
intestine and five colon tissue samples, obtained from https://
www.ebi.ac.uk/arrayexpress/ (accession code E-MTAB-1733 (25)
were used as controls (Supplementary Material, Table S4).
Raw reads were quality and adapter trimmed with cutadapt
(v1.16) in Trim Galore (v0.5.0) (36). Low-quality read-ends
were removed using a Phred score cut-off of 30. Adapters
were trimmed using the first 13 bp of the standard Illu-
mina paired-end adapters. Trimmed reads were HISAT2
(v2.1.0) aligned to gencode.v27lift37.annotations. StringTie
(v1.3.4) was used to calculate the coverages at the transcripts
(Supplementary Material, Table S10). Statistical testing was
performed for small intestine and colon sample sets separately
using DESeq2 (v1.14.1). Two designs were used: (i) ∼ group +
individual (ii) ∼ group + genotype. Group was defined as normal
or tumor for small intestine samples and as normal, hyperpolyp
or adenoma for colon samples. Tumor versus normal test results
are from design (i) and Del versus Wt results are from design (ii).
Single cell gene expression analysis
Fresh tissue samples (Supplementary Material, Table S4) were
dissociated with gentleMACS™ Octo Dissociator with heaters
(Miltenyi Biotec) using the human Tumor Dissociation Kit (#130–
095-929, Miltenyi Biotec), following the manufacturer’s protocol
‘Dissociation of soft tumors’. Cell suspensions were strained
with a 70 μm cell strainer and centrifuged at 300rcf for 5 min.
Red blood cells were lyzed by incubating in the ACK lysing
buffer for 5 min. Cells were washed (centrifugation at 300rcf
for 5 min) and diluted in 1× PBS (phosphate-buffered saline)
with 0.04% BSA (bovine serum albumin) and filtered through
a 40 μm Flowmi™ Tip strainer. Cell count and viability was
measured by LUNA-FL™ Dual Fluorescence Cell Counter (Logos
Biosystems). The Single Cell 3’RNAseq library preparations were
done using the Chromium™ Single Cell 3’ Reagent 2 chemistry
and sequenced on Illumina NovaSeq 6000 with read lengths:
26 bp (Read 1), 8 bp (i7 Index), 0 bp (i5 Index) and 91 bp (Read
2) at FIMM.
Data processing and analysis were performed using 10x
Genomics Cell Ranger (v2.1.1) pipelines. Cell Ranger ‘cellranger
mkfastq’ was used to produce FASTQ (raw data) files and
‘cellranger count’ to align, filter and count unique molecular
identifiers (UMIs); mkfastq was run using Illumina bcl2fastq
(v2.2.0) and reads aligned against human genome GRCh38. The
processed data was plotted in R (v3.3.3) using cellrangerRkit
(v1.1.0). For heatmaps, the five most up-regulated genes in
each k-means 10 cluster were prioritized based on P-value. Only
genes with mean normalized UMI counts per cell exceeding 0.5
were considered. Before visualization of WNT2, CFTR, OLFM4 and
EPHB2 signature across all cells, the expression of genes with at
least one UMI count was normalized for each barcode and log2
transformed. Cluster ID determination and cell counting was
performed in Loupe Cell Browser (10x Genomics, v2.0.0). Cluster
IDs were determined based on expression of known intestinal
cell markers. In the cell counting, all cells with least one unique
molecular identifier count were considered.
RNA in situ hybridization
RNA in situ hybridization was performed on fresh 5 μm FFPE tis-
sue sections using the RNAscope Multiplex Fluorescent Reagent
Kit v2 (Advanced Cell Diagnostics, Inc.). The Hs-WNT2 (#584071,
ACD), Hs-CFTR (#603891-C2, ACD), positive control probe mix (3-
plex Positive Control Probe- Hs #320861, ACD) or negative control
probe mix (3-plex Negative Control Probe #320871, ACD) were
hybridized for 2 h at 40◦C, followed by signal amplification and
developing according to the manual. Tyramide signal amplifi-
cation (TSA) Plus Cyanine 3 or Cyanine 5 fluorophores (Perkin
Elmer) were used at 1:750 and 1:3500 dilutions, respectively.
The sections were counterstained with DAPI and mounted with
ProLong Gold Antifade Mountant. Representative areas were
scanned using 3DHISTECH Pannoramic 250 FLASH II digital slide
scanner at Genome Biology Unit (Helsinki, Finland) and a Plan-
Apochromat objective with PCO.edge 4.2 camera with 1 × 40
magnification in 7 focus levels, and CaseViewer (v2.2) was used
to create images from the scanned slides. Different tissue types
were stained and scanned in separate batches. Identical image
settings were used in images created from the same staining and
scanning batches. Details of the image settings are described in
the figure legends.
Organoid culture
Biopsies were minced and incubated in 10 mM EDTA-PBS
solution for 2.5 h on ice during which buffer was changed
every 20–30 min. Epithelial crypts were isolated by vigorous
shaking and pipetting the tissue with a 10 mL serological
pipette. Epithelium was pelleted and washed once with ‘basal
media’: Dulbecco’s Advanced DMEM/F12 (Life) containing 10 mM
Hepes, penicillin and streptomycin and 1x Glutamax (Life).
The epithelial preparation was resuspended in basal media
supplemented with 1 × B27 (Life), 1 × N2 (Life), 50 ng/ml EGF
(RnD), 100 ng/ml noggin (Peprotech), 500 ng/ml R-spondin1
(RnD), 1 μM N-Acetyl-L-Cystein (Sigma), 500 nM A-83-01 (Sigma),
10 μM SB202190 (Sigma), 1 mM Nicotinamide (Sigma), 10 μM
Leu-Gastrin (Sigma), 3 μM Chir99021 (Sigma), hereafter ‘organoid
media’ and mixed with Matrigel® (Corning) in 2:3 ratio. About,
20 μL drops of Cell-Matrigel® mixture were plated on a 48-
well plate and let to solidify for 15 min at +37◦C. Drops were
overlaid with 300 μL of organoid media containing 10 μM Y-
27632 (Sigma) during the first two days after isolation. Media was
changed every 2–3 days. Approximately once a week, organoids
were mechanically broken and subcultured in 1:3 ratio. WNT-
dependent organoid growth was analyzed from subcultured
organoids overlaid with organoid media containing various
concentrations of Chir99021 or vehicle (dimethyl sulfoxide
[DMSO]), as indicated in respective figures and figure legends.
Media was changed after two days and organoid survival
assessed after four days in culture.
Single cell sorting
Grown organoids were collected to 15 mL falcon tubes, spun
down and broken by pipetting repeatedly with 200 μL pipette.
Organoid fragments were washed once with cold PBS and
digested by incubating in 150 μL of TrypLE Express (Life) for
15 min at +37◦C. Single cells were isolated from aggregates
by pipetting with a 200 μL pipette. TrypLE Express was
inactivated and washed away with 2 mL of basal media.
Single cells were resuspended in basal media containing a
1:500 dilution of APC conjugated rat anti-human CD44 (clone:
IM7, eBioscience). Cells were incubated for 15 min on ice
followed by washing with basal media. Cells were labeled with
dead cell dye, SYTOX™ Blue (Thermo Scientific), 1:500 in 2%
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SYTOX™ Blue−CD44+cells were sorted and resuspended in
organoid media lacking Chir99021 and containing 10 μM Y-
27632. Cell suspension was mixed with Matrigel™ and 5 μL drops
containing 1000 cells were plated on a 96-well plate and let to
solidify for 15 min at +37◦C. 100 μL of organoid media lacking
Chir99021 and containing 10 μM Y-27632 and supplemented
with Chir99021 or IWP-2 (Sigma) as indicated in the respective
figures and figure legends was overlaid. Media was changed
every 2 days and organoid formation was quantified on Day 6
(Supplementary Material, Fig. S6).
Supplementary Material
Supplementary Material are available at HMG online.
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